Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-453 | TNBC | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9723.124 | 1.0407 | 1.0828 | 0.9827 | |
| MDA-MB-453 | TNBC | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9723.124 | 1.0343 | 1.0698 | 0.9827 | |
| MDA-MB-453 | TNBC | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9723.124 | 1.0158 | 1.0322 | 0.9827 | |
| MDA-MB-453 | TNBC | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9723.124 | 0.9817 | 0.9627 | 0.9827 | |
| MDA-MB-453 | TNBC | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 9723.124 | 1.1022 | 1.2081 | 0.9827 | |
| MDA-MB-453 | TNBC | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 9723.124 | 1.0356 | 1.0724 | 0.9827 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7904.018 | 0.9295 | 0.8987 | 1.4056 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7904.018 | 1.1285 | 1.1796 | 1.4056 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7904.018 | 0.8665 | 0.8061 | 1.4056 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7904.018 | 1.1585 | 1.2207 | 1.4056 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7904.018 | 1.0555 | 1.0784 | 1.4056 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7904.018 | 1.0744 | 1.1048 | 1.4056 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7904.018 | 0.9969 | 0.9956 | 1.4056 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.137 | uM | 7904.018 | 1.0654 | 1.0923 | 1.4056 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.685 | uM | 7904.018 | 0.8052 | 0.7142 | 1.4056 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7905.018 | 0.8487 | 0.6664 | 0.8988 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7905.018 | 0.9447 | 0.8773 | 0.8988 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7905.018 | 0.7471 | 0.4459 | 0.8988 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7905.018 | 1.0545 | 1.1217 | 0.8988 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7905.018 | 1.1804 | 1.4054 | 0.8988 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7905.018 | 1.1272 | 1.2850 | 0.8988 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7905.018 | 1.0776 | 1.1735 | 0.8988 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.137 | uM | 7905.018 | 1.0654 | 1.1460 | 0.8988 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.685 | uM | 7905.018 | 0.8123 | 0.5870 | 0.8988 | |
| MDA-MB-468 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7906.018 | 0.6214 | 0.1847 | 0.9087 |